News >

Adjuvant Immunotherapy Combinations on Horizon for Melanoma

Silas Inman
Published: Thursday, Nov 07, 2019

Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD
Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.1

In addition to this adjuvant study, the combination of nivolumab and ipilimumab is being examined prior to surgery in the phase II OpACIN-neo study, Weber noted. This trial will look at a variety of doses for the combination with a primary end point focused on the occurrence of grade 3/4 immune-related AEs (NCT02977052).

References

  1. Weber JS. Adjuvant Therapy for Melanoma. Presented at: 37th Annual CFS®, hosted by Physicians’ Education Resource®, LLC; November 6-8, 2019; New York, New York.
  2. Long GV, Hauschild A, Santinami M, et al. Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma. Ann Oncol. 2018;29(suppl 8;abstr LBA43). doi: 10.1093/annonc/mdy424.053.
  3. Schadendorf D, Hassel JC, Fluck M, et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED). Ann Oncol. 2019;30(suppl 5;abstr LBA67). doi: 10.1093/annonc/mdy394.064.
<<< View more from the 2019 Chemotherapy Foundation Symposium
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x